Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with radiotherapy versus durvalumab plus tremelimumab with radiotherapy in unresectable locally advanced HPV-negative head and neck squamous cell carcinoma
2016-003175-22Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-003175-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003175-22.